InspireMD, Inc. (NSPR)
| Previous Close | 2.0700 |
| Open | 1.9800 |
| Bid | 0.0000 x 900 |
| Ask | 0.0000 x 1400 |
| Day's Range | 1.9800 - 2.0700 |
| 52 Week Range | 1.8000 - 6.8200 |
| Volume | |
| Avg. Volume | 17,459 |
| Market Cap | 16.896M |
| Beta (5Y Monthly) | 1.41 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.0800 |
| Earnings Date | Aug 08, 2022 - Aug 12, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.25 |
- GlobeNewswire
InspireMD Provides Highlights from Recent Presentations and Live Case Transmission at LINC 2022
Successful live case transmission again demonstrated CGuard’s™ differentiated patient protection features and ease of useTEL AVIV, Israel, June 09, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today provided the following highlights from multiple presentations and live case transmission, all featuring its CGuard™ Embolic Prevention Stent System, from LINC 2022, which was held June 6-9. “Our partici
- GlobeNewswire
InspireMD’s CGuard™ Embolic Prevention Stent System to be Featured in Clinical Presentations and a Live Case Transmission at LINC 2022
Live case transmission designed to demonstrate ease-of-use and exceptional patient safety features of CGuard™ Embolic Prevention System (EPS)TEL AVIV, Israel, June 02, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today announced that the company will participate in the Leipzig Interventional Course (LINC) 2022, which is being held June 6-9 in Leipzig, Germany. The company will occupy Booth #36 duri
- GlobeNewswire
InspireMD Reports First Quarter 2022 Financial Results and Business Update
- 20% growth in CGuard™ revenue Year-over-Year - - C-Guardian FDA IDE Trial Completes First European Enrollment - - Held Key Opinion Leader (KOL) Webinar on Carotid Artery Disease Management and Stroke Prevention, highlighting CGuard™ clinical advantages - - European logistics hub established with BOMI Group –for direct market access as well as establishing the commercial footprint for a growing portfolio of new systems across different channels – - Upcoming Clinical Evidence and Live Case to be
